A.R.T. Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

A.R.T. Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-186,918	Closed	-$822K	–	1773
2018 Q3	$822K	Buy	+186,918	New	+$1.04M	0.04%	664
2018 Q2	–	Sell	-266,510	Closed	-$1.37M	–	1858
2018 Q1	$1.37M	Buy	+266,510	New	+$1.9M	0.06%	537
2017 Q4	–	Sell	-123,455	Closed	-$209K	–	1758
2017 Q3	$209K	Buy	+123,455	New	+$227K	0.01%	1122

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

A.R.T. Advisors's SRNE Position: Q4 2018 in Review

A.R.T. Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 186,918 shares — an estimated $822K sold.

A.R.T. Advisors first reported a position in SRNE in Q3 2017 and held it in 3 quarters. The position peaked at $1.37M in Q1 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

A.R.T. Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 186,918 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $822K.
A.R.T. Advisors first reported a position in Sorrento Therapeutics, Inc. in Q3 2017 and held it in 3 quarters.
A.R.T. Advisors's Sorrento Therapeutics, Inc. position peaked at $1.37M in Q1 2018.
78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.